The Myasthenia Gravis Rare Disease Network (MGNet) aims to enhance therapeutic development for Myasthenia Gravis (MG) by partnering with academic centers, foundations, other research groups, and industry. Its mission encompasses improving clinical trial tools, finding disease biomarkers for better treatment prediction, educating young investigators on rare diseases, and raising awareness about MG's unique patient needs.
MGNet's Pilot and Feasibility Grants program is geared towards funding innovative, early-stage investigations into Myasthenia Gravis (MG). Its priorities are to identify treatment-responsive biomarkers, assess and improve clinical measures to enhance clinical trial readiness, and evaluate therapeutic interventions for the distinct sub-types of MG. The program seeks proposals that align with MGNet's resources and focus on clinical and translational research, excluding animal studies. Up to two grants will be funded, each at $75,000 for a 12-month period, with the possibility of renewal based on performance and fund availability.